The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients
Abstract
PURPOSE: To describe thyroid eye disease (TED)-like orbital inflammatory syndrome in 3 cancer patients treated with immune checkpoint inhibitors. METHODS: All consecutive patients treated by the senior author who were receiving immune checkpoint inhibitors and developed TED-like orbital inflammation were included. RESULTS: Three cancer patients treated with immune checkpoint inhibitors developed orbital inflammation. The first patient was treated with a combination of a cytotoxic T-lymphocyte antigen-4 inhibitor and a programmed cell death protein 1 inhibitor and developed TED-like orbital inflammation with normal thyroid function and antibody levels. The second patient had a previous diagnosis of Graves disease without TED, and developed TED soon after initiating treatment with a programmed cell death protein 1 inhibitor. The third patient developed acute hyperthyroidism with symptomatic TED following treatment with an investigational cytotoxic T-lymphocyte antigen-4 inhibitor agent. All 3 patients were managed with either systemic steroids or observation, with resolution of their symptoms and without the need to halt immune checkpoint inhibitor treatment for their cancer. DISCUSSION AND CONCLUSIONS: TED-like orbital inflammation may occur as a side effect of immune checkpoint inhibitor therapy with anti-cytotoxic T-lymphocyte antigen-4 or anti-PD-1 inhibitors. To the best of their knowledge, this is the first reported case of TED as a result of programmed cell death protein 1 inhibitor monotherapy. All 3 patients were treated with systemic steroids and responded quickly while continuing treatment with immune checkpoint inhibitors for their cancer. With increasing use of this class of drugs, clinicians should be familiar with the clinical manifestations and treatments for this adverse reaction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To the best of our knowledge, there is only one reported case of pre-existing Graves’ hyperthyroidism before ICPi treatment [42].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [42]
In the citing paper
“This patient had a history of GD one year before immunotherapy; he commenced Nivolumab in a euthyroid state but experienced a recurrence of thyrotoxicosis with GO that evolved to hypothyroidism, despite persistent positive TRAbs.”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [42]
In the citing paper
“The only case with an association of induced hyperthyroidism and orbitopathy was reported by Sagiv et al. and was treated with glucocorticoids, and hyperthyroidism resolved spontaneously [42].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [42]
Citations
Cites
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 569
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Long, G. V., Atkinson, V. G., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 248
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93
Learning from the “tsunami” of immune checkpoint inhibitors in 2015
Kourie, H. R., Awada, G., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.017 · Cited by 42
Wang, H., Zhu, L., Cheng, J.-W., Cai, J.-P., Li, Y., Ma, X., & Wei, R.-L. (2015) · Current Eye Research · doi:10.3109/02713683.2014.993767 · Cited by 9
Cited by
Sorted by citations
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C., Lupi, I., Paschou, S. Α., Tóth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 216
Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 139
Orbital Myositis: A Comprehensive Review and Reclassification
McNab, A. A. (2019) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001429 · Cited by 100
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 92
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Martens, A., Schauwvlieghe, P., Madoe, A., Casteels, I., & Aspeslagh, S. (2023) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-022-00321-2 · Cited by 68
Metadata
- Authors
- Sagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., & Esmaeli, B.
- Affiliations
- Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery
- Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
- Department of Surgical Oncology
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sagiv, Oded
- Kandl, Thomas J.
- Thakar, Sudip D.
- Thuro, Bradley A.
- Esmaeli, Bita
- ORCID
- Venue
- Ophthalmic Plastic & Reconstructive Surgery
- Published
- 2019-01
- Volume
- 35
- Issue
- 1
- Pages
- 50-52
- ISSN
- 0740-9303 (ISSN-L)
- OpenAlex
- W2808870673
- Cited by
- 71
- References
- 10
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 18 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 8 · 2019: 4
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Ophthalmic Plastic and Reconstructive Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Keywords
- Graves' ophthalmopathy, orbital inflammation, immune checkpoint inhibitors, CTLA-4 inhibitors, PD-1 inhibitors, Graves' disease, hyperthyroidism, extraocular muscle enlargement, adverse drug reactions, corticosteroid therapy, cancer patients
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Humans, Male, Middle Aged, Neoplasms, Oculomotor Muscles, Tomography, X-Ray Computed, Radioimmunotherapy, Graves Ophthalmopathy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
